Male, n (%) |
64 (54.7) |
Age, years |
67 [57, 75] |
BMI, kg/m2
|
20.1±10.6 |
LVEF, % |
59 [39, 60] |
OAC therapy, n (%) |
39 (33.3) |
AF type |
|
Paroxysmal AF, n (%)
|
58 (49.6)
|
Short-term persistent AF, n (%)
|
20 (17.1)
|
Long-term persistent AF, n (%)
|
39 (33.3)
|
CHA2DS2-VASc score |
3 [2, 5] |
Congestive heart failure, n (%)
|
26 (22.2)
|
Hypertension, n (%)
|
85 (72.6)
|
Age
|
|
≥75, n (%) |
36 (30.8) |
65-75, n (%) |
46 (39.3) |
Diabetes mellitus, n (%)
|
31 (26.5)
|
Stroke/TIA, n (%)
|
49 (41.9)
|
Vascular disease, n (%)
|
19 (16.2)
|
HAS-BLED score |
2 [1, 3] |
Abnormal liver function, n (%)
|
0
|
Abnormal renal function, n (%)
|
6 (5.1)
|
Bleeding, n (%)
|
13 (11.1)
|
Labile INR, n (%)
|
8 (6.8)
|
Drug use, n (%)
|
38 (32.5)
|
Alcohol abuse, n (%)
|
9 (7.7)
|